Long-term inhibition of intestinal lipase by orlistat improves release of gut hormones increasing satiety in obese women.
Journal Title: Pharmacological Reports - Year 2013, Vol 65, Issue 3
Abstract
Background: Reduced postprandial secretion of peptide YY (PYY), glucagon-like peptide-1 (GLP-1), cholecystokinin, and increased hunger was reported after a single dose of orlistat, an inhibitor of intestinal lipase. As yet, the influence of long-term therapy with orlistat on PYYand GLP-1 release has not been studied. Our study was aimed at assessing the influence of 8-week therapy with orlistat as a component of a weight loss program on pre-prandial circulating PYY and GLP-1 levels. Methods: Forty obese women, without concomitant diseases, were randomly allocated to groups receiving orlistat or placebo during an 8-week weight management program. Body mass, body composition and plasma levels of PYY, GLP-1 and insulin (for QUICKI calculation) were determined prior to and at the end of therapy. Results: Women treated with orlistat obtained significantly greater body and fat mass loss than those receiving placebo (9.0 ± 3.1 vs. 5.9 ± 3.2% and 21.9 ± 10.9 vs. 7.4 ± 15.6%, respectively). Only in those treated with orlistat a slight, but significant increase of the QUICKI was found (8.0 ± 16.5 vs. -0.1 ± 12.7 %, respectively). Weight loss was followed by a significant increase of plasma levels of PYY and GLP-1 in group treated with orlistat, and was about 2-times greater than receiving placebo. The increase was independent of body mass changes. Conclusion: The long-term inhibition of intestinal lipase by orlistat increases the pre-prandial levels of GLP-1 and PYY, independent of body mass changes. Therefore, it seems that long-term treatment with orlistat may exert hunger suppressing and insulin sensitizing incretin effect beyond weight reduction.
Authors and Affiliations
Magdalena Olszanecka-Glinianowicz, Piotr Dąbrowski, Joanna Janowska, Mike Smertka, Krzysztof Jonderko, Jerzy Chudek
Keywords
Related Articles
- EP ID EP130824
- DOI -
- Views 103
- Downloads 0
Advanced glycation and retinal pathology during diabetes.
Of all microvascular complications of diabetes mellitus, retinopathy remains the most common. This disease presents major therapeutic problems for the ophthalmologist and despite many decades of intense research it still...
Human micro- and macrovessel-derived endothelial cells: a comparative study on the effects of adrenaline and a selective adenosine A(2)-type receptor agonist under normoxic and hypoxic conditions.
Adrenaline is a highly effective stimulator of cyclic AMP (cAMP) production in microvascular endothelial cells (ECs) - HMEC-1, showing only a moderate activity in macrovascular ECs - HUVEC. In both EC preparations, adren...
Inflammatory lipid mediators in ischemic retinopathy.
Ischemic proliferative retinopathy develops in various retinal disorders, including retinal vein occlusion, diabetic retinopathy and retinopathy of prematurity. Ischemic retinopathy remains a common cause of visual impai...
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis - guidelines vs. reality.
Background: The aim of the study was to analyze the effectiveness of lipid-lowering therapy and therapeutic decisions made by physicians for patients not achieving LDL targets. Methods: 11,768 patients undergoing therapy...
Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan.
Background: This study evaluates the pharmacokinetics (PK) and ocular disposition of paracetamol and paracetamol glucuronide in diabetic rabbits. Methods: Thirty two New Zealand rabbits were divided into four groups: con...